Application Number INFORMATION DISCL Confirmation Number STATEMENT BY APA Filing Date December 14, 2004 Form PTO-1449 (Modified) GEDULIN, Bronislava First Named Inventor (Use several sheets if necessary) 1646 Group Art Unit Examiner Name Not yet assigned Ruixiang L of 54061.8101.US01 Sheet Attorney Docket No.

					U.S	. PATENT DOCUMENTS				
Examiner	Cite	e		Code		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document Date of Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear		or	
RLi	AA				Bala	asubramaniam	Oct. 24, 1994			
	, ,	+				en gang meleberakan kepada		· 10. 204 244554 · 1444554 · 144455 · 144455 · 144455 · 144455 · 144455 · 144455 · 144455 · 144455 · 144455 · 144455	Urrigin intensit	Carrier of
		 								
	<u></u>				ODE	GN PATENT DOCUMENTS		<u> </u>		
Examiner	Cite		eign Patent or Ap	plication		Name of Patentee or Applicant	Date of Publication or Filing Date of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant		
Initials*	No.	Office_	NUMBER	(if kı	nown)	of Cited Document	Document	Figures Appear	├ ┤	
									\sqcup	
									Ш	
			OTHER PR	IOR A	\RT-N	ION PATENT LITERATURE D	OCUMENTS			
Examiner Initials*	Cite No.	(boo	Include name of took, magazine, jour	he auth nal, ser	or (in (ial, syr	APITAL LETTERS), title of the article nposium, catalog, etc.), date, page(s), and/or country where published.	(when appropriate) volume issue numb	, title of the item per(s), publisher, city	Т	
RLi	AB	and Y2	UMONT et al., Peptide YY derivatives as selective neuropeptide Y/peptide YY Y1 agonists devoided of activity for the Y3 receptor subtype. Brain Res. Mol. rain Res. Oct. 1994, Vol. 26, Issue 1-2, pp. 320-324.							
RLi	AC		_HY et al., F , pp. 397-40		le Y	in gastrointestinal disord	ers. Peptide	s,-Feb2002,	i frica bismojaš	iza dvijeko
٠,										
	-		····							
							· :			
			· · · · · · · · · · · · · · · · · · ·							

EXAMINER		DATE CONSIDERED				
	Rudxiang Lj	7/8/206				
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not					
	considered. Include copy of this form with next communication to application(s).					

	INFORMATION STATEMENT E Form PTO-14	AP ANT	EB 2 8 2005				
((Use several sheets if necessity)						
	1	of	1				

Sheet

	COMPLETE IF KNOWN
Application Number	10/518,128
Confirmation Number	
Filing Date	December 14, 2004
First Named Inventor	Gedulin, Bronislava
Group Art Unit	1646
Examiner Name	Notyetassigned Ruixiang Li
Attorney Docket No.	54061.8101.US01

Ternent, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal							U.S	. PATENT DOCUMENTS		-	
Examiner Initials* Office NUMBER (If known) OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. RLi AB El-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242, 413-419. AB Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. Dig Dis Sci 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55. Terment, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Heoanal				Cite Kind Code		ind Code	Name of Patentee or Inventor		Publication or Filing Date of Cited	Where Relevant Passages	or
Examiner Initials* OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. AB El-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242, 413-419. AB Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. Dig Dis Sci 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55. Terment, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal		+									
Examiner Initials* Cite No. Office NUMBER Kind Code (If known) OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. RL- AA El-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242, 413-419. AB Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. Dig Dis Sci 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55. Terment, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal	Mar. 1				• • •	F	ORE	IGN PATENT-DOCUMENTS	min no constant state of	ないできなからなっていないである。 ないできない。 ないでもない。 ないでもな	477 500
OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. AA EI-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. <i>J Intern Med</i> 242, 413-419. AB Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. <i>Dig Dis Sci</i> 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. <i>Jpn J Med</i> 27, 49-55. Ternent, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Heoanal		1 -				Kind	Code		Publication or Filing Date of Cited	Where Relevant Passages or Relevant	T
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. RLi AA EI-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242, 413-419. AB Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. Dig Dis Sci 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55. Tement, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal		1	-	02	TYOMBE.	7	[0.0000000000000000000000000000000000000	Document	i igulos rappour	\dagger
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. RLi AA EI-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. <i>J Intern Med</i> 242, 413-419. AB Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. <i>Dig Dis Sci</i> 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. <i>Jpn J Med</i> 27, 49-55. Tement, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal			\int	·							\prod
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. RLi AA EI-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. <i>J Intern Med</i> 242, 413-419. AB Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. <i>Dig Dis Sci</i> 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. <i>Jpn J Med</i> 27, 49-55. Tement, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal											
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. RLi AA EI-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242, 413-419. Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. Dig Dis Sci 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55. Terment, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal		\perp									
Cite Initials* (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. T AA EI-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242, 413-419. Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. Dig Dis Sci 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55. Ternent, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal			_							On a fab - Name	
AA EI-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. <i>J Intern Med</i> 242, 413-419. Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. <i>Dig Dis Sci</i> 33, 1322-1328. Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. <i>Jpn J Med</i> 27, 49-55. Tement, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal				(bool	k, magazine, je	ournal, ser	ial, syr	mposium, catalog, etc.), date, page(s),	(when appropriate), volume issue numb	, title of the item per(s), publisher, city	Т
Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. <i>Jpn J Med</i> 27, 49-55. Ternent, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal			E					ling, R. and Grimelius, L. (1997	') Colonic endor	crine cells in	
AC Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55. Terment, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal		АВ									\prod
Ternent, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal	200	AC Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 27, 49-55.									
1 1 1	1	AD	L	Ternent, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S.,							
Teshima, H., Tari, A., Sumii, K., Yoshihara, M., Ohgoshi, H., Fukuhara, I., Tokumo, K., Haruma, K., Kajiyama, G., Miyachi, Y. and et, a.l. (1987) [Plasma peptide YY-like immunoreactivity in ulcerative colitis, colorectal cancer, and colectomy]. Nippon Shokakibyo Gakkai Zasshi 84, 2681-2687.	R ₁ Kajiyama, G., Miyachi, Y. and et, a.l. (1987) [Plasma peptide YY-like immunoreactivity in ulcerative						activity in ulcerative	***			

EXAMINER		DATE CONSIDERED				
	Ruixiang Li	7/8/206				
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).					

PTO/SB/08A (07-05) Approved for use through 07/31/2008. OMB 0661-0031

Under the Paperwort	k Reduction Act of 1995, no persons <u>are requi</u> red	U.S. Petent and Trades to respond to a collection of informa	merk Office; U.S. DEPARTMENT OF CO tion unless it contains a velid CMB cont	OMMERCE TOLINATE OF	
Substitute for form	1449/PTO	Complete if Known			
Consumo for form 1443F FO		Application Number	10/518,128		
INFORM	ATION DISCLOSURE	Filing Date	June 13, 2003		
		First Named Inventor	Bronislava Gedulin		
	IENT BY APPLICANT	Art Unit	1646		
(Uso a	es many sheets as necessary)	Examiner Name	LI, RUIXIANG		
Sheet 1	of 2	Attorney Docket Number	0402-UTL-5		

				DOCUMENTS	
Examiner Initials*	Citte No.1	Document Number Number-Kind Code ^{2 of Instance}	Publication Date MM-DD-YYYY	Name of Patentas or Applicant of Cited Document	Pages, Columna, Unas, Where Relevant Passages or Relevant Figures Appear
RLI		US- 2003/0224983 A1	12-4-2003	Nielsen, Hoiriis Jens	
RLi		^{US-} 6,569,832 B1	05-27-2003	Knudsen et al.	
		US-			
		US-			
		U\$-			
		US-			
		US-			<u> </u>
		US-			
		US-			
		US-			
	<u> </u>	US-			
		US-	1		
		Us-			<u> </u>
		UŞ-	- 	<u> </u>	
	 	us-	 	<u> </u>	-

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Data	Name of Petentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code [®] Teurpher [®] "Find Code [®] (If Anown)	MM-DD-YYYY		Or Relevant Figures Appaar	T°
						₽
						┡
						┡
						⊨
				<u> </u>	<u></u>	

Examiner Signature	Ruixiang	Wi	Date Constitered	7/8/2006

"EXAMMER: Initial I reference considered, whether or not clistion is in conformance with MPEP 609. Draw line through clistion if not in conformance and not considered, include copy of this form with need communication to applicant. "Applicant a unique clistion designation number (options!). "See Kinds Codes of USPTO Patent Documents at www.ispto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-tetter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible." Applicant is to place a check mark here if English tanguage Translation is intached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submilling the completed application from the USPTO. Time will vary depending upon the individual case. Any comments and Trademark Office, P.O. Box 1450, Abscandia, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Abscandia, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

PTO/SB/08B (07-06)
Approved for use through 07/31/2008. OMB 0551-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control marrier. Complete if Known Substitute for form 1449/PTO **Application Number** 10/518,128 INFORMATION DISCLOSURE Filing Date June 13, 2003 STATEMENT BY APPLICANT First Named Inventor Bronislave Gedulin Art Unit 1646 (Use as many cheets as necessary) Examiner Name LI, RUIXIANG **Attomey Docket Number** Sheet 2 **af** 12 0402-UTL-5

NON PATENT LITERATURE DOCUMENTS					
Examiner initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
RLi		Towfigh et al., Surgical Forum Vol. 50: 25-27 (1999)			
	,				
	·				
		·			

Examiner	2	Date	101
Signature	Kuixiang hi	Considered	7/8/2006

"EXAMPLES: trilial if reference considered, whether or not citation to in conformance with MPEP 609. Drawline through citation if not in conformance and not

*EXAMPLER: Initial if reference considered, whether or not disting to in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (aptional). 2 Applicant is to place a check mark here if English language Translation is statched.

This collection of information is required by 97 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including againsting, preparing, and submitting the completed application form to the USPTO. Three will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Tradament Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 (1-800-788-9199) and select option 2.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of Substitute for form 1449/PTO

Sheet 1

1995, no persons are

APR 0 3 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/518,128

Filing Date June 13, 2003

First Named Inventor Bronislava Gedulin

Art Unit 1646

Examiner Name LI, RUIXIANG

Attorney Docket Number 0402-UTL-5

Examiner	Cite	Document Number	Publication Date	F DOCUMENTS Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.	Number-Kind Code ^{2 (I known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
RLi		^{US-} 4,683,195	7-28-1987	Mullis et al.	
1		^{US-} 4,683,202	7-28-1987	Mullis	
		US- 4,839,343	6-13-1989	Waeber et al.	
		^{US-} 4,891,357	01-02-1990	Kala	
		^{US-} 4,892,538	01-09-1990	Aebisher et al.	
.		^{US-} 5,459,039	10-17-1995	Modrich et al.	
		^{US-} 5,498,531	03-12-1996	Jarrell .	
		^{US-} 5,574,010	11-12-1996	McFadden	
		^{US-} 5,696,093	12-09-1997	Tseng	
		^{US-} 5,824,784	10-20-1998	Kinstler et al.	
		^{US-} 5,824,778	10-20-1998	Ishikawa et al.	
		^{US-} 5,912,227	06-15-1999	Croom, Jr. et al.	\ .
l		^{US-} 5,939,462	08-17-1999	Connell et al.	
T		^{US-} 5,968,819	10-19-1999	Gerald et al.	
		us- 5,980,945	11-9-1999	Ruiz	. \
T		^{US-} 6,013,622	01-11-2000	Bruno et al.	. \
		^{US-} 6,315,203	11-13-2001	lkeda et al	. \
¥		^{US-} 6,355,478	03-12-2002	Baez et al.	
RLi		^{US-} 6,391,343	05-21-2002	Yen	

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁸ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
RY		EP 0 992 239 B1	03-12-2003	Banyu Pharma Co Ltd		
1		WO 83/04053	11-24-1983	Applied Molecular Genetic		
		WO 89/01967	03-09-1989	Brown University Research		Г
		WO 90/02580	03-22-1990	Brown University Research		
		WO 90/15637	12-27-1990	Brown University Research		
RL;		WO 91/10425	07-25-1991	Brown University Research		F

Examiner Signature	Ruiting L.	Date Considered 7/8/200	6

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ŝ

Substitute for form 1449/PTO		Complete if Known		
		Application Number	10/518,128	
INFORMATION DISCLOSURE		Filing Date	June 13, 2003	
	-	First Named Inventor	Bronislava Gedulin	
STATEMENT BY APPLICANT	ENT BY APPLICANT	Art Unit	1646	
(Use as many sheets as necessary)		Examiner Name	LI, RUIXIANG	
Sheet 2	of 31	Attorney Docket Number	0402-UTL-5	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1	Number-Kind Code ^{2 (8 known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
RLI		^{US-} 6,420,532	07-16-2002	Gerald et al.	
		^{US-} 6,558,708 B1	05-06-2003	Lin	
		^{US-} 6,734,166	05-11-2004	Croom, Jr. et al.	
*		^{US-} 2002/0094346-A1	07-18-2002	Lin	
RL;		^{US-} 2004/0228846	11-18-2004	Pang et al.	
		US-			
,		US-			
		UŞ-			
		US-			
		US-			***************************************
-		US-			
		US-			
		US-			
		US-			
		US-			
		US-	· · · · · ·		
		US-			
		US-	1		
		US-	 		

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
_RLi		WO 91/10470	07-25-1991	Brown University Research		
(WO 94/16101	07-21-1994	Hubert Koster		Г
		WO 99/07404	02-18-1999	Amylin Pharmaceuticals, I		Г
		WO 99/15516	04-01-1999	Banyu Pharma Co Ltd		
\		WO 99/25727	05-27-1999	Amylin Pharmaceuticals, I		Γ
RLi		WO 99/25728	05-27-1999	Amylin Pharmaceuticals, I		↸

Examiner
Signature

| Date | Considered | 7/8/206

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴Applicant is to place a check mark here if English tanguage Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
,	Application Number	10/518,128	
INFORMATION DISCLOSURE	Filing Date	June 13, 2003	
	First Named Inventor	Bronislava Gedulin	
STATEMENT BY APPLICANT	Art Unit	1646	
(Use as many sheets as necessary)	Examiner Name	LI, RUIXIANG	
Sheet 3 of 31	Attorney Docket Number	0402-UTL-5	

Examiner	Cite No.	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (F known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
		US-			
		US-	 		
		US-			-
		US-	_		
•	<u> </u>	US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
***************************************		US-			
		US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
				Or Relevant Figures Appear	Τ°	
RLi		WO 00/47219	08-17-2000	Ontogeny, Inc.		Т
1		WO 00/68197	11-16-2000	Ortho McNeil Pharm		
		WO 01/62737	08-30-2001	Ortho McNeil Pharm		Г
		WO 01/76631	10-18-2001	Cedars Sinai Medical		
*		WO 03/026591 A2	04-03-2003	Imperial College		abla
RLi		WO 03/057235	05-17-2003	Imperial College		

Rustiang Examiner Date 7/8/2006 Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the relign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449/PTO	Complete if Known		
		Application Number	10/518,128	
	INFORMATION DISCLOSURE	Filing Date	June 13, 2003	
		First Named Inventor	Bronislava Gedulin	
	STATEMENT BY APPLICANT	Art Unit	1646	
	(Use as many sheets as necessary)	Examiner Name	LI, RUIXIANG	
$\overline{}$	Sheet 4 of 31	Attorney Docket Number	0402-UTL-5	

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		Number-Kind Code ^{2 (# known)} US-			, ignority co.
	•	US- 			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			
······································		US-			
		US-			
	1	US-			
		US-		, ,,,,,	
· · · · · · · · · · · · · · · · · · ·	 -	US-	1		
		US-	1		***
		US-		······································	
		US-			
	 -	US-	 		

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	e Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ "Number ⁴ "Kind Code ⁸ (if Innown)	MM-DD-YYYY			10
RLi		WO 03/105763	12-24-2003	Amylin Pharmaceuticals, I		
						匚
				ļ		L

Examiner Signature	Rushing Li	Date Considered	7/8/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *FkInd of document to the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			ct of 1995, no persons a	re required to respond to a collection	of Information unless it contains a valid OMB control number. Complete if Known
Subsut	rte for form 1449/PTO			Application Number	10/518,128
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	Otas as many at			Art Unit	1646
	(Use as many si	ieets as r	recessary)	Examiner Name	LI, RUIXIANG
Sheet	5	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RLi		Adrian, T.E., et al., Gastroenterology 89, 1070-1077 (1985)	
		Adrian, T.E., et al., Digestion 21, 214-218 (1981)	
		Ahren, B. et al., Eur J Endocrinol 134, 362-365 (1996)	
		Allen, J.M., et al., Digestion 30, 255-262 (1984)	
		Ando, R., et al., Eur J Pharmacol 427, 53-59 (2001)	
		Andres, C.J., et al., Bioorg Med Chem Lett 13, 2883-2885 (2003)	
		Aponte, G.W., et al., FASEB J 3, 1949-55 (1989)	
		Aponte, G.W. Peptides 23, 367-376 (2002)	
1		Asakawa, A., et al., Peptides 20, 1445-1448 (1999)	
RLi	. \	Bader, R., et al., Biochemistry 41, 8031-8042 (2002)	

Examiner	Ω `- \ Δ	Date	7/2/2
Signature	Ruchang In	Considered	1/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTO	udion A	at of 1000, no paraons as		Complete if Known
(0000000	10 10 10 11 1 1 1 0 1 0 1 0 1 0 1 0 1 0			Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many sheets as necessary)			Art Unit	1646
	(038 as many site	1063 03 11	iocossary)	Examiner Name	LI, RUIXIANG
Sheet	6	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	-	Γ²
RLi		Balasubramaniam, A., et al., Peptides 14, 1011-1016 (1993)		
	-	Balasubramaniam, A., et al., Int J Pept Protein Res 29, 78-83 (1987)		
		Balasubramaniam, A., et al., Pept Res 1, 32-35 (1988)		
		Balasubramaniam, A., et al., Peptides 23, 1485-1490 (2002)		
		Balasubramaniam, A., et al., J Med Chem 43, 3420-3427 (2000)		
		Balasubramaniam, A.A. Peptides 18, 445-457 (1997)		
		Barany, F. Proc Natl Acad Sci U S A 88, 189-193 (1991)		
		Bartlett PA, et al., Bioorg Chem.14:356-377 (1986)	Ī	
		Batterham, R.L., et al., N Engl J Med 349, 941-948 (2003)	T	
RL;		Batterham, R.L., et al., Nature 418, 650-654 (2002)	1	\

Examiner	2 0	Date	1.1
Signature	Kushang In-	Considered	7/8/206

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB contains at valid OMB contains

Substitu	Officer the Paperwork Reduction Act of 1995, no persons substitute for form 1449/PTO NFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known	
000000				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she		oogseend.	Art Unit	1646
	(Use as many and	70 CS 83 F	ecessary)	Examiner Name	LI, RUIXIANG
Sheet	7	of	31	Attorney Docket Number	0402-UTL-5

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	Ī	T²
		number(s), publisher, city and/or country where published.	Ļ	_
RLj		Beck, A., et al., FEBS Lett 244, 119-122 (1989)		
		Beck-Sickinger, A.G., et al., J Recept Res 13, 215-228 (1993)	Π	
		Beltowski, J. et al., Pol J Pharmacol 56, 5-27 (2004)	Ī	
i		Berge, S.M., et al., J Pharm Sci 66, 1-19 (1977)	Ī	
		Berglund, M.M., et al., Exp Biol Med (Maywood) 228, 217-244 (2003)		
		Bertrand, G., et al., Pancreas 7, 595-600 (1992)		
		Birdsall, N.J.M. et al., Trends Pharmacol Sci 4, 459-463 (1983)	Ħ	
		Bischoff, A. et al., Trends Pharmacol Sci 20, 104-106 (1999)		
		Bonaz, B., et al., Neurosci Lett 163, 77-80 (1993)	T	\
RL;		Bottcher, G., et al., Pancreas 4, 282-288 (1989)	Ī	1

Examiner	Ruis ine of	Date	7/8/206
Signature	maning du	Considered	1/01-6

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Onsidered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/I				Complete if Known
7 0000000000000000000000000000000000000			Application Number	10/518,128
INFORMATI	ON DIS	CLOSURE	Filing Date	June 13, 2003
STATEMENT BY APPLICANT		First Named Inventor	Bronislava Gedulin	
Also se mon	ny sheets as n	encascant)	Art Unit	1646
(030 83 1181	iy siloots as i	accossary)	Examiner Name	LI, RUIXIANG
Sheet 8	of	31	Attorney Docket Number	0402-UTL-5

	1	NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
RLi		Boublik, J.H., et al., J Med Chem 32, 597-601 (1989)	
1		Bourguet E, et al., Bioorg Med Chem Lett.13:1561-1564 (2003)	
		Bousquet-Melou, A., et al., J Lipid Res 36, 451-461 (1995)	
		Brown, K.K., et al., Diabetes 48, 1415-1424 (1999)	
		Cabrele, C. et al., J Pept Sci 6, 97-122 (2000)	
		Cabrele, C., et al., J Biol Chem 275, 36043-36048 (2000)	
		Cabrele, C., et al., Biochemistry 41, 8043-8049 (2002)	
		Cabrele, C., et al., Peptides 22, 365-378 (2001)	
1		Camilleri, M., et al., Gut 22, 14-18 (1981)	
RLi		Campfield, L.A., et al., Science 269, 546-549 (1995)	1

-			
Examine Signatur	Keep of Comb 7	Date 7/8/2006	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The state of the s

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Subatitu	ite for form 1449/PTC				Complete if Known
3005010	NFORMATION DISCLOSURE		Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many s	haate as s	ooossand	Art Unit	1646
	(ose as many s		1000338177	Examiner Name	LI, RUIXIANG
Sheet	9	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		τ²
RLi		Chance WT, et al., Life Sci.58:1785-1794 (1996)	N	
		Chen, C.H. et al., Am J Physiol 269, R787-R792 (1995)		
		Chen, C.H., et al., Regul Pept 61, 95-98 (1996)		
		Chen, C.H., et al., Neurogastroenterol Motil 9, 109-116 (1997)		•
		Chen, M.H., et al., Sensitive Gastroenterology 87, 1332-1338 (1984)		
		Chen, Z., et al., FEBS Lett 492, 119-122 (2001)		
		Clark, J.T., et al., Endocrinology 115, 427-429 (1984)	Ī	
		Clark, J.T., et al., Regul Pept 17, 31-39 (1987)		
		Conlon, J.M. Peptides 23, 269-278 (2002)		
RLi		Cook, D.L. et al., Nature 311, 271-273 (1984)		-

Examiner	2 2	Date	7/8/ /
Signature	Kindling L.	Considered	1/8/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ite for form 1449/PTO				Complete if Known
00000			•	Application Number	10/518,128
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin
	(Use as many st	oote se i	nococcan/i	Art Unit	1646
	(030 03 mony a			Examiner Name	LI, RUIXIANG
Sheet	10	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RLi		Corp, E.S., et al., Peptides 22, 493-499 (2001)	
		Corp, E.S., et al., Am J Physiol 259, R317-R323 (1990)	
		Coruzzi, G., et al., Arch Int Pharmacodyn Ther 302, 232-241 (1989)	
		Cotton, R.G. Mutat Res 285, 125-144 (1993)	
		Cotton, R.G., et al., Proc Natl Acad Sci U S A 85, 4397-4401 (1988)	
		Cox, H.M. et al., Br J Pharmacol 101, 247-252 (1990)	
		Cox, H.M., et al., J Physiol 398, 65-80 (1988)	
		Cox, H.M., et al., Regul Pept 75-76, 3-8 (1998)	
		Dea, D., et al., Gastroenterology 96, 695-703 (1989)	
RLi		Deng, X., et al. Dig Dis Sci 46, 156-165 (2001)	1

			· · · · · · · · · · · · · · · · · · ·
Examiner	2	Date	- / . /
Signature	Kindiang L	Considered	7/8/206

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Aboxandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PT				of Information unless it contains a valid OMB control number. Complete if Known
Cubsul	10 10 10 11 144 2F 1	·		Application Number	10/518,128
INF	ORMATIC	N DIS	SCLOSURE	Filing Date	June 13, 2003
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many	ekoote on a	occessor)	Art Unit	1646
	(USO ES MENY	S116612 62 1	lecassary)	Examiner Name	LI, RUIXIANG
Sheet	11	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RLi		Dox, I.G., et al., Definition of 'islet'. In: Anonymous The HarperCollins Illustrated Medical Dictionary, 1st edn. pp. 227 New York: HarperCollins Publishers, Inc.] (1993)	
		Dumont, Y., et al., Eur J Pharmacol 238, 37-45 (1993)	
		Dumont Y, et al., Society for Neuroscience Abstracts. 1993;19:726. Abstract 299.8.	
		Eberlein, G.A., et al., Peptides 10, 797-803 (1989)	
		Ebert, R. Z Gastroenterol Verh 23, 165-170 (1988)	
		Eto, B., et al., Peptides 16, 1403-1409 (1995)	
		Fackelmann USA Today, Health and Science Gut hormone could curb urge to overeat. (Aug 7 2002)	
		Feinstein, R.D., et al., J Med Chem 35, 2836-2843 (1992)	
1		Ferber, S., et al., Journal of Biological Chemistry 269, 11523-11529 (1994)	
RLi		Fournier, A., et al., Mol Pharmacol 45, 93-101 (1994)	

Examiner Signature	Rushing L.	Date Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	(Use as many sheets as necessary)		Complete if Known .			
				Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICAN		PPLICANT	First Named Inventor	Bronislava Gedulin	
	NFORMATION DISCLOSUR TATEMENT BY APPLICAN (Use as many sheets as necessary)	accessor)	Art Unit	1646		
	(Ose as many a			Examiner Name	LI, RUIXIANG	
Sheet	12	of	31	Attorney Docket Number	0402-UTL-5	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
RL;		Freshney, R.I. (Ed.) Culture of Animal Cells: A Manual of Basic Technique, pp. 4 New York: Alan R. Liss, Inc] (1983)	
-		Garlicki, J., et al., Am J Physiol 258, E40-E4 (1990)	
		Gedulin, B., et al., Gastroenterology 108, A604 (1995)	
		Gehlert, D.R. Proc Soc Exp Biol Med 218, 7-22 (1998)	
		Gibbs, R.A., et al., Nucleic Acids Res 17, 2437-2448 (1989)	
		Gobbi, M., et al., J Neurochem 72, 1663-1670 (1999)	
		Gold, G., et al., Diabetes 30, 77-82 (1981)	
		Gomez, G., et al., Am J Physiol 268, G71-G81 (1995)	
		Goodlad RA, et al., Digestion. 46 Suppl 2:177-181 1990	1
RLi	1	Gordon, E.A., et al., Neurosci Lett 119, 187-190 (1990)	

			·
Examiner	0 -0:	Date	1. 1
Signature	Kindling L	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

	der the Paperwo		ct of 1995, no persons as		of information unless it contains a valid ON Complete if Known	
Subsuit	ite ici icini 1449	PIO		Application Number	10/518,128	
INF	ORMAT	ION DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
	//ha aa			Art Unit	1646	
	(Use as many sheets as necessary)			Examiner Name	LI, RUIXIANG	
Sheet	13	of	31	Attomey Docket Number	0402-UTL-5	

-	1 000	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
RLi		Grandt, D., et al., Regul Pept 51, 151-159 (1994)	
		Grandt, D., et al., Biochem Biophys Res Commun 186, 1299-1306 (1992)	
		Greeley, G.H. Jr, et al., Proc Soc Exp Biol Med 189, 325-328 (1988)	
		Greeley, G.H. Jr, et al., Am J Physiol 254, E513-E517 (1988)	
		Grieco P, et al., Tetrahedron Lett.43:6297-6299 (2002)	
		Groth, C.G., et al., Transplant Proc 24, 972-973 (1992)	1
		Grouzmann, E., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 519B (1993)	
		Grundemar, L., et al., Regul Pept 62, 131-136 (1996)	
		Gu X, et al., Tetrahedron Lett. 44:5863-5866 (2003)	
RLi		Guan, D., et al., Endocrinology 128, 911-916 (1991)	

Examiner	2	Δ	Date	-101-	
Signature	Kending	, Tu	Considered	7/8/2006	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449/PTO	,		Complete if Known		
0000000				Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	(Use as many sheets as necessary)			First Named Inventor	Bronislava Gedulin	
				Art Unit	1646	
				Examiner Name	LI, RUIXIANG	
Sheet	14	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS		1
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	, T ²	
RLi		Gue, M., et al., Br J Pharmacol 118, 237-242 (1996)	144022011311	and a tensisian of the life is the second
		Gustavsson, S., et al., Scand J Gastroenterol 12, 993-997 (1977)		
		Hagan, M.M. et al., Pharmacol Biochem Behav 45, 941-944 (1993)		
		Halaas, J.L., et al., Science 269, 543-546 (1995)		
		Halatchev, I.G., et al., Endocrinology 145, 2585-2590 (2004)		
		Hanessian S, et al., Tetrahedron 53:12789-12854 (1997)		
		Harding, R.K. et al., Peptides 10, 21-24 (1989)		
		Haynes, J.M., et al., Br J Pharmacol 122, 1530-1536 (1997)		
	T	Henry, M., et al., Obes Res 13, 36-47 (2005)		केंग्रह देशक विकास सम्बद्ध के विकास स्थानित है
RLi		Hoentjen, F., et al., Scand J Gastroenterol 35, 166-171 (2000)		

Examiner Signature	Rusting L	Date Considered	7/8/206
ACMANIATO. I.		14 14DED 000 D 11 44 1 1 44	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO		ct of 1995, no persons ar	Complete if Known		
Judani	10 10 10 11 144 31 10			Application Number	10/518,128	
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
	(Use as many she	ote ne i	nocassarvi	Art Unit	1646	
	(Osa as many sno	- CO 63 1	iocessary)	Examiner Name	LI, RUIXIANG	
Sheet	15	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T²	
RL;		Holliday, N.D. et al., Br J Pharmacol 119, 321-329 (1996)			·
. (Hsu, I.C., et al., Carcinogenesis 15, 1657-1662 (1994)		Lings no	Back from Generalistics of the Company of the Sec
		Hu, Y., et al., J Biol Chem 271, 26315-26319 (1996)			
		Hughes, S.D., et al., Proceedings of the National Academy of Sciences of the United States of America 89, 688-692 (1992)			
		Inui, A. Trends Pharmacol Sci 20, 43-46 (1999) :			
		lyengar, S., et al., J Pharmacol Exp Ther 289, 1031-1040 (1999)			
		Jackerott, M. et al., Endocrinology 138, 5013-5018 (1997)			·
		Jackerott, M., et al., J Histochem Cytochem 44, 809-817 (1996)			
		Johnson, J.H., et al., Science 250, 546-549 (1990)			
RLi		Jones, P.M. et al., Endocr Rev 19, 429-461 (1998)	S. Pagari	35 (15.2)	Brann Jam Tambalika nga Mas alika nga tambalika

Examiner	0 '4' 1	Date	7/0/200
Signature	Kushing Li	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{2.} Available: Include to reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including athering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

and the same and the street from a

Complete Age Complete Contraction

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 10/518,128

INFORMATION DISCLOSURE
Filing Date June 13, 2003

First Named Inventor Bronislava Gedulin

1646

(Use as many sheets as necessary)

Sheet 16 of 31 Attorney Docket Number 0402-UTL-5

Art Unit

		NON PATENT LITERATURE DOCUMENTS		
xaminer nitials*	als* No.1 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²	
RLi		Kanatani, A., et al., Biochem Biophys Res Commun 272, 169-173 (2000)		
		Kanatani, A., et al., Biochem Biophys Res Commun 266, 88-91 (1999)		
		Kanatani, A., et al., Endocrinology 141, 1011-1016 (2000)		
		Karlsson S, et al., Acta Physiol Scand.157:305-306 (1996)		केटर - १९९५ रेटस-वेस्टर ५ रेडवर दिस्किश
		Kato, K., et al., Peptides 16, 1257-1262 (1995)		
		Kawakubo, K., et al., Brain Res 854, 30-34 (2000)		
		Keire, D.A., et al., Peptides 23, 305-321 (2002)		
		Keire, D.A., et al., Biochemistry 39, 9935-9942 (2000)		
		Keire, D.A., et al., Am J Physiol 279, G126-G131 (2000)		
RLi		Kimmel, J.R., et al., Endocrinology 83, 1323-1330 (1968)		

Examiner	0 0	Date	
Signature	Kinding In	Considered 7/8/2008	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Comment of the State of the

a the formers of the particular a

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PTO			Complete if Known			
0000				Application Number	10/518,128		
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003		
STA	TEMENT B	SY A	PPLICANT	First Named Inventor	Bronislava Gedulin		
	(lites as many sho	ote se r	accesand	Art Unit	1646		
	(Use as many sheets as necessary)			Examiner Name	LI, RUIXIANG		
Sheet	17	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹			Γ²
RL;		Kirby, D.A., et al., J Med Chem 36, 3802-3808 (1993)		
		Kirby, D.A., et al., J Med Chem 38, 4579-4586 (1995)	1	
		Kopelman, P.G. Nature 404, 635-643 (2000)		
		Korsgren, O., et al., Transplantation 45, 509-514 (1988)	17	
÷	· .	Krasinski, S.D., et al., Mol Endocrinol 5, 433-440 (1991)		ve.
		Krstenansky, J.L., et al., Proc Natl Acad Sci U S A 86, 4377-4381 (1989)		
		Krstenansky, J.L., et al., Neuropeptides 17, 117-120 (1990)		=
		Kruger, D.F., et al., Diabetes Educ 25, 389-397; quiz 398 (1999)		
		Kumagai Braesch, M., et al., Transplant Proc 24, 679-680 (1992)	T	
RL;		Kushi, A., et al., Proc Natl Acad Sci U S A 95, 15659-15664 (1998)		\ \

Examiner	2	Date	
Signature	Kendeling In	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiallity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO						
000000	10 10 10 11 144 21 10			Application Number	10/518,128	
INFO	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
				Art Unit	1646	
(Use as many sheets as necessary)		Examiner Name	LI, RUIXIANG			
Sheet	18	of	31	Attorney Docket Number	0402-UTL-5	Span to consider addition states

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RL; Lac		Lacy, P.E., et al., Science 254, 1782-1784 (1991)		
		Landegren, U., et al., Science 241, 1077-1080 (1988)		
		Leban, J.J., et al., J Med Chem 38, 1150-1157 (1995)		
		Leibowitz, S.F. et al., Peptides 12, 1251-1260 (1991)		
		Liu, C.D., et al., J Gastrointest Surg 5, 147-152 (2001)		
		Liu, X.M., et al., Diabetes 40, 858-66 (1991)	e handlest #2	panemingan nggi candangan ngarin
		Lloyd, K.C.K., et al., Am J Physiol 270, G123-G127 (1996)		
		Lluis, F., et al., Gastroenterology 94, 137-144 (1988)		
		Lundberg, J.M., et al., Proc Natl Acad Sci U S A 79, 4471-4475 (1982)		
RL;		Lundell, I., et al., J Biol Chem 270, 29123-29128 (1995)		

			<u>.</u>
Examiner Signature	Rusking L.	Date Considered	7/8/206

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PTO			Complete if Known		
000000	10 10 10 11 17 10 10			Application Number	10/518,128	
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
	(lien as many cha	oto ao a	andream)	Art Unit	1646	
(Use as many sheets as necessary)			ucussary)	Examiner Name	LI, RUIXIANG	
Sheet	19	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	and a high print of	be. A reversion continue
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Service Court Flore Court
RLi		Lyznicki JM, et al., Am Fam Physician. 63:2185-2196 (2001)		
		Makimura, H. et al., Obesity Poster Abstract No. 118 "Adrenalectomy stimulated hypothalamic proopiomelanocortin mRNA but does not correct obesity in diet-induced obese mice."		
		Malaisse-Lagae, F., et al., Experientia 33, 915-917 (1977)		
		Markison S., et al., Obesity Poster Abstract No. 119 "Selective melanin-concentrating hormone receptor antagonists decrease feeding in rodents."		
		Marsh, D.J., et al., Nat Med 4, 718-721 (1998)		
		Martin, J.R. Brain Res 1002, 11-20 (2004)		
		Martin, N.M., et al., Int J Obes Relat Metab Disord 28, 886-893 (2004)		
		Mashiko, S., et al., Endocrinology 144, 1793-1801 (2003)		gaza i em legen ette i est filippenni
		Mashiko et al., Obesity Poster Abstract No. 120 "Characterization of neuropeptide Y Y5 receptor mediated obesity in mice."		
RLi		Maxam, A.M. et al., Proc Natl Acad Sci U S A 74, 560-564 (1977)		

Examiner Signature	Rushing L	Date Considered	7/8/2016

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SE/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/518,128	
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
	(Use as many she	ate ae r	neresean)	Art Unit	1646	
		Examiner Name	LI, RUIXIANG			
Sheet	20	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	Ţ
RL;		Mazelin L, et al., J Auton Nerv Syst.73:38-45 (1998)	K Palestape a.	i Sangtin esperatu na Lisabana (tar.).
		Medeiros, M.D. et al., Endocrinology 134, 2088-2094 (1994)		
		Michel, M.C., et al., Pharmacol Rev 50, 143-150 (1998)		
7.		Morley, J.E. Neuropsychobiology 21, 22-30 (1989)		,
		Morley, J.E. et al., Life Sci 41, 2157-2165 (1987)		
		Morley, J.E., et al., Am J Physiol 267, R178-R184 (1994)		
		Morley, J.E., et al., Brain Res 341, 200-203 (1985)		
		Morris GP, et al., Gastroenterology 96:795-803 (1989)		,
	1	Mulder, H., et al., Microscopy-Research and Technique 43, 313-324 (1998)	IANG IST	tere om eriode et tregeneriste e
RL;		Mullins, D., et al., Mol Pharmacol 60, 534-540 (2001)		

Examiner		Date	1 1
Signature	Kushang In	Considered	7/8/2006
<u> o.g. iata. o</u>		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ad to respond to a collection of information unless it contains a valid OMB control number.

	rte for form 1449/PTO		ar or rood, no porsons a	Complete if Known		
, Sansaia	ile ioi ioini 144sir 10			Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
	##			Art Unit	1646	
	(Use as many si	reets as n	lecessary)	Examiner Name	LI, RUIXIANG	
Sheet	21	of	31	Attorney Docket Number	0402-UTL-5	

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
		number(s), publisher, city and/or country where published.	'
RLi		Munson, P.J. et al., Anal Biochem 107, 220-239 (1980)	
		Murakami, Y., et al., J Med Chem 42, 2621-2632 (1999)	10 23123 4
		Murase, S., et al., J Biochem (Tokyo) 119, 37-41 (1996)	
		Myers, R.M., et al., Science 230, 1242-1246 (1985)	
		Myers, R.M., et al., Nature 313, 495-498 (1985)	
		Naeve, C.W., et al., Biotechniques 19, 448-453 (1995)	
		Nakajima, M., et al., J Pharmacol Exp Ther 268, 1010-1014 (1994)	
		Nakazawa, H., et al., Proc Natl Acad Sci U S A 91, 360-364 (1994)	
*		Naslund, E., et al., Int J Obes Relat Metab Disord 23, 304-311 (1999)	
RLi		Ngo, J.T., et al., The protein folding problem and tertiary structure prediction, pp. 491-495. Boston: Birkhauser (1994)	رة أوران مرد

Examiner	0.	Date	7/0/21
Signature	Kushang In	Considered	1/8/236

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WITH HEREBOOKEN

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI.

Substitu	Substitute for form 1449/PTO			Complete if Known				
- Colonia of Control o				Application Number	10/518,128	Ì		
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	*-		
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin			
				Art Unit	1646			
(Use as many sheets as necessary)			· ·	Examiner Name	LI, RUIXIANG			
Sheet	22	of	31	Attorney Docket Number	0402-UTL-5			

	0:4-	NON PATENT LITERATURE DOCUMENTS		
xaminer iitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RLi		Nieuwenhuizen, A.G., et al., Diabetologia 37, 871-878 (1994)		-
		Nightingale, J.M., et al., Gut 39, 267-272 (1996)		
		Odagiri, H., et al., J Biol Chem 271, 1909-1915 (1996)		
		Okada, S., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 520B (1993)		ing. I'm egy ifa 1987 <u>lin</u> g
		Okumura, T., et al., Neuroscience Letters 178, 167-170 (1994)		
		Orita, M., et al., Proc Natl Acad Sci U S A 86, 2766-2770 (1989)		
		Otonkoski, T., et al., Diabetes 37, 286-291 (1988)		
		Pappas, T.N., et al., Gastroenterology 91, 1386-1389 (1986)		
		Pappas, T.N., et al., Am J Physiol 248, G118-G123 (1985)		
RLi	1	Parker, E.M., et al., Eur J Pharmacol 349, 97-105 (1998)		

Examiner Signature	Rushing L	Date Considered 7/8/2006	-

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

- The same of the party of the con-

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO				re required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Subsulu	te for form 1445/P10	•		Application Number	10/518,128
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	**			Art Unit	1646
	(Use as many si	neets as r	iecessary)	Examiner Name	LI, RUIXIANG
Sheet	23	of	31	Attorney Docket Number	0402-UTL-5

Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²	
nitiais	NO.	number(s), publisher, city and/or country where published.		
RLI		Parker, E.M., et al., Peptides 21, 393-399 (2000)		•
		Parker, S.L. et al., Can J Physiol Pharmacol 78, 150-161 (2000)		
		Pelleymounter, M.A., et al., Science 269, 540-543 (1995)		
		Pheng, L.H., et al., Br J Pharmacol 139, 695-704 (2003)		į
		Pironi, L., et al., Gastroenterology 105, 733-739 (1993)	و عرب منتر بوي او	ya, milan in istaasai
		Pi-Sunyer, F.X. Obes Surg 12 Suppl 1, 6S-11S (2002)		
		Pokrovsky, V.I. Nephrotomy: renal insufficiency. In: Academician of RAMS, (Ed.) Small Medical Encyclopedia, pp. 59-62. Moscow: Meditisina Publishers] (1996) - English tra		
		Potter, E.K., et al., Eur J Pharmacol 267, 253-262 (1994)		
1		Randle, P.J. Diabetes Metab Rev 14, 263-283 (1998)		è
RLi		Renshaw, D. et al., Curr Drug Targets 6, 171-179 (2005)		

Examiner Signature	Runding L	Date Considered	7/8/2016

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and when the complete of the complete of the chief Information Officer, U.S. Patent and when the complete of the complete of the chief Information Officer, U.S. Patent and when the complete of the chief Information Officer, U.S. Patent and when the complete of the chief Information Officer, U.S. Patent and when the complete of the chief Information Officer, U.S. Patent and when the complete of the chief Information Officer, U.S. Patent and when the chief Information Officer, U.S. Patent and the chief Information Officer, U.S. Patent and the chief Informati

PTO/SB/08B (07-05)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			persons an	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known	
Substitute for form 1449/PTO					Application Number	10/518,128
INFORMATION DISCLOSURE					Filing Date	June 13, 2003
STA	STATEMENT BY APPLICANT			ANT	First Named Inventor	Bronislava Gedulin
	(Use as many sheets as necessary)				Art Unit	1646
(Usa as many sheats as necessary)				Examiner Name	LI, RUIXIANG	
Sheet	24.	of	31	5	Attorney Docket Number	0402-UTL-5

		NAME OF TENT I ITEM A TUDE DACUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
RLi		Rhodes, C.J. et al., J Cell Biol 105, 145-153 (1987)		
		Rico, L. et al., Obesity Poster Abstract No. 117 "Early and dissociated leptin and insulin resistance in transgenic mice overexpressing leptin from keratinocytes."		
		Rissanen, A., et al., BMJ 301, 835-837 (1990)		
		Rist, B., et al., Eur J Biochem 247, 1019-1028 (1997)		
		Rist, B., et al., FEBS Lett 394, 169-173 (1996)		,
		Robbins, L.S., et al., Pathologic Basis of Disease, 3rd edn. pp. 972-990. Philadelphi: W. B. Saunders Company] (1984)		
		Saiki, R.K., et al., Nature 324, 163-166 (1986)		es , m car var na ge
		Saiki, R.K., et al., Proc Natl Acad Sci U S A 86, 6230-6234 (1989)		
		Sainsbury, A., et al., Genes Dev 16, 1077-1088 (2002)		
RLi		Saleeba, J.A. et al., Methods Enzymol 217, 286-295 (1993)		

Examiner	0 ' ' D	Date	2/8/201
Signature	Kuiscang Li	Considered	718 2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Onsidered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

THE KIND OF MALL AT INVOICE OF SHAREST POPULATION AND AND AND STREET

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/518,128 **Filing Date** June 13, 2003 **First Named Inventor** Bronislava Gedulin

INFORMATION DISCLOSURE STATEMENT BY APPLICANT **Art Unit** 1646 (Use as many sheets as necessary) **Examiner Name** LI, RUIXIANG **Attorney Docket Number** Sheet 25 31 0402-UTL-5 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate); title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-iss number(s), publisher, city and/or country where published.		L ₅
RLi		Sandberg M, et al., J Med Chem.41:2481-2491 (1998)	
		Sander, M., et al., Proc Natl Acad Sci U S A 95, 11572-11577 (1998)	
		Sanger, F., et al., Proc Natl Acad Sci U S A 74, 5463-5467 (1977)	
		Sato, N., et al., J Med Chem 46, 666-669 (2003)	
		Savage, A.P., et al., Gut 28, 166-170 (1987)	
		Scatchard, G., Ann NY Acad Sci 51, 660 (1949)	
		Scheen, A.J. Drugs 54, 355-368 (1997)	
		Schmidt PT, et al., Eur J Gastroenterol Hepatol 17:207-212 (2005)	· Sales St. S.
1		Schuit, F.C. Horm Res 46, 99-106 (1996)	
RL;		Schwartz, M.W., et al., Nature 404, 661-671 (2000)	
	<u> </u>		

Examiner	Puivic a li	Date	7/8/2.1
Signature	Much and Di	Considered	1181226

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ite for form 1449/PTO			Complete if Known			
Judani	10 101 101111 144 17			Application Number	10/518,128		
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin		
	(Use as many she	ate se n	acaccand	Art Unit	1646		
	(Ose as many site	TO 63 11	ecossary)	Examiner Name	LI, RUIXIANG		
Sheet	26	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	and the survey of the States
RLi		Servin, A.L., et al., Endocrinology 124, 692-700 (1989)		
		Shan, L., et al., Science 297, 2275-2279 (2002)		
		Sheikh, S.P. Am J Physiol 261, G701-G715 (1991)		
		Silva, A.P., et al., Clin Chim Acta 326, 3-25 (2002)		
		Simeonovic, C.J. et al., Aust J Exp Biol Med Sci 60 Pt 4, 383-390 (1982)		
		Slack, J.M. Development 121, 1569-1580 (1995)		·
		Small, C.J., et al., Proc Natl Acad Sci U S A 94, 11686-11691 (1997)		
		Soll, R.M., et al., Eur J Biochem 268, 2828-2837 (2001)	Contraction of	ber I'm esterda est listigativ
		Souers AJ, et al., Tetrahedron 57:7431-7448 (2001)		
RLi		Stanley, B.G., et al., Peptides 6, 1205-1211 (1985)		

			· ·
Examiner		Date	-1.1
Signature	Rushans L.	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

- all the rolling world .

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork Red	luction A	ct of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Subsult	ite for form 1445/P1O			Application Number	10/518,128		
INF	ORMATION	I DIS	CLOSURE	Filing Date	June 13, 2003		
STA	ATEMENT I	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin		
				Art Unit	1646		
	(Use as many sh	eers as i	iecessary)	Examiner Name	LI, RUIXIANG		
Sheet	27	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ²	
RLi		St-Onge, M.P. et al., J Nutr 132, 329-332 (2002)		
		Sullivan, S.J., et al., Science 252, 718-721 (1991)		
		Surwit, R.S., et al., Metabolism - Clinical and Experimental 44, 645-651 (1995)		
		Suzuki, T., et al., Gastroenterology 85, 114-121 (1983)	Congressive St.	on, is not easy the edy files
		Taniguchi, H., et al., Eur J Pharmacol 312, 227-233 (1996)		
		Tatemoto, K. Proc Natl Acad Sci U S A 79, 2514-2518 (1982)		1
		Tatemoto, K. Proc Natl Acad Sci U S A 79, 5485-5489 (1982)		
		Tatemoto, K., et al., Nature 296, 659-660 (1982)		·
		Tatemoto, K., et al., Proc Natl Acad Sci U S A 89, 1174-1178 (1992)		
RL;		Tatemoto, K., et al., Biochem Biophys Res Commun 157, 713-717 (1988)		

Examiner Signature	Ruixing L	Date Considered	7/8/2-6

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

the contract the second contract company to the contract the contract to

man a garage many .

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
b a collection of information unless it contains a valid OMB control number.

	ite for form 1449/PTO				Complete if Known			
Juban	ile ioi ioini 144a/F10			Application Number	10/518,128			
INF	ORMATION	N DIS	CLOSURE	Filing Date	June 13, 2003			
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin			
	(Use as many sh		occessori	Art Unit	1646			
	(Use as many sn	reers as r	lecessary)	Examiner Name	LI, RUIXIANG			
Sheet	28 [.]	of	31	Attorney Docket Number	0402-UTL-5			

		NON PATENT LITERATURE DOCUMENTS		
Examiner nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
RLi		Taylor, I.L. J Dairy Sci 76, 2094-2101(1993)		
		Taylor, I.L. et al., Am J Physiol 248, G277-G280 (1985)		
		Teyssen, S., et al., Pancreas 13, 80-88 (1996)		
	٠	Thorens, B., et al., Proceedings of the National Academy of Sciences of the United States of America 87, 6492-6496 (1990)	<i> </i>	
		Thum, A., et al., Exp Clin Endocrinol Diabetes 110, 113-118 (2002)		
		Tito JM, et al., Am J Surg.165:690-696 (1993)		Spanist Confederation of Contract
		Totheroh, G., "Science Offers Promising Treatment for an Overweight Nation" CBN News (Sept 4, 2003)		
		Tsai JH, et al., Bioorg Med Chem 7:29-38 (1999)		
		Tschop, M., et al., Nature 430, 1 p following 165; discussion 2 p following 165 (2004)		
RLi		Tseng, W.W. et al., Peptides 23, 389-395 (2002)		

|--|

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Ur	der the Paperwork f	Reduction A	ct of 1995, no persons ar		of information unless it contains a valid OM	
Substitu	ite for form 1449/PT	0			Complete if Known	
500 500	10 101 101111 141011 1	•		Application Number	10/518,128	
INF	ORMATIC	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
	// las as mass.	-b4		Art Unit	1646	
	(Use as many	sneets as I	iecessa <i>ry)</i>	Examiner Name	LI, RUIXIANG	
Sheet	29	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RLi		Tuch, B.E., et al., J Endocrinol 132, 159-167 (1992)			
İ		Turnbull, A.V., et al., Diabetes 51, 2441-2449 (2002)		•	
		Ueno, N., et al., Gastroenterology 117, 1427-1432 (1999)			
		Upchurch, B.H., et al., Development 120, 245-252 (1994)			
		Valera, A., et al., J Biol Chem 269, 28543-28546 (1994)			
		Valet, P., et al., J Clin Invest 85, 291-295 (1990)			
		van Santbrink, E.J. et al., J Clin Endocrinol Metab 82, 3597-602 (1997)			
		Verchere, C.B., et al, Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 517B., (1993)			
		Virgilio AA, et al., Tetrahedron 53:6635-6644 (1997)			
RLi		Voisin, T., et al., J Biol Chem 268, 20547-20554 (1993)			

Examiner	Oi i a P	Date/	
Signature	Righting L.	Considered	16 12066

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

0402-UTL-5

Substitute for form 1449/PTO	Complete if Known				
Substitute for form 1443/F10	Application Number	10/518,128			
NFORMATION DISCLOSURE	Filing Date	June 13, 2003			
STATEMENT BY APPLICANT	First Named Inventor	Bronislava Gedulin			
	Art Unit	1646			
(Use as many sheets as necessary)	Examiner Name	LI, RUIXIANG			

Attomey Docket Number

31

Sheet

130

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RLI		Wager-Page, S.A., et al., Can J Physiol Pharmacol 71, 768-775 (1993)			
		Wahoff, D.C., et al., Transplant Proc 26, 804 (1994)			
		Walker, M.W., et al., J Neurosci 8, 2438-2446 (1988)			
		Walker, M.W., et al., Peptides 18, 609-612 (1997)			
		Wang, Z.L., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 518B (1993)			
		Weinberg, D.H., et al., J Biol Chem 271, 16435-16438 (1996)			
		Wells, J.A. Biochemistry 29, 8509-8517 (1990)			
		Widdowson, P.S., et al., Brain Res 778, 242-250 (1997)			
*		Wilding, J.P. Diabet Med 19, 619-627 (2002)			
RLi		Wiley, J.W., et al., Gastroenterology 100, 865-872 (1991)	T		

Examiner	ρ	Δ.	Date	7/11/1
Signature	Kushang	L-	Considered	116/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known			
000344	10 101 101111 14431 10			Application Number	10/518,128		
INF	ORMATION	N DIS	CLOSURE	Filing Date	June 13, 2003		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Bronislava Gedulin		
(Use as many sheets as necessary)				Art Unit	1646		
				Examiner Name	LI, RUIXIANG		
Sheet	31	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-iss number(s), publisher, city and/or country where published.				
RLi		Wilson, J.D., et al., Diabetes 38 Suppl 1, 217-219 (1989)				
		Wimalawansa, S.J. Crit Rev Neurobiol 11, 167-239 (1997)				
		Yang, H., et al., Br J Pharmacol 123, 1549-1554 (1998)				
		Yang, H. et al., Am J Physiol 268, G943-G948 (1995)				
		Yoshinaga, K., et al. Am J Physiol 263, G695-G701 (1992)				
		Young, A.A. et al., Program and Abstracts, 10th International Congress of Endocrinology 419 (poster P2-58) (1996)				
		Young, A.A., et al., Metabolism 45, 1-3 (1996)				
		Zai, H., et al., Regul Pept 61, 181-188 (1996)				
		HYPERDICTIONARY – definition of "Structure Activity Relationship"				
RLi		On-Line Medical Dictionary. Dept. of Oncology, University of Newcastle upon tyne. The Cancerweb Project Copyright 1997-2004 (definitions of "hyperlipoproteinaemia"; "hyperlip				

Examiner	0	Date	-1.45
Signature	Rustiang Li	Considered	7/16/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.